Beijing Tiantan Biological Products Co., Ltd. (600161.SS)

CNY 20.69

(-1.0%)

Market Cap (In CNY)

40.91 Billion

Revenue (In CNY)

5.18 Billion

Net Income (In CNY)

1.1 Billion

Avg. Volume

9.11 Million

Currency
CNY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
20.166666-27.6
PE
-
EPS
-
Beta Value
0.365
ISIN
CNE000000WF9
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Dao Xing Fu
Employee Count
-
Website
https://www.tiantanbio.com
Ipo Date
1998-06-16
Details
Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.